3/16
04:26 pm
tgtx
This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop [Yahoo! Finance]
Neutral
Report
This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop [Yahoo! Finance]
3/10
08:12 am
tgtx
BRIUMVI Momentum Leads to Strong Execution for TG Therapeutics (TGTX) [Yahoo! Finance]
Low
Report
BRIUMVI Momentum Leads to Strong Execution for TG Therapeutics (TGTX) [Yahoo! Finance]
3/9
12:35 pm
tgtx
Is TG Therapeutics (TGTX) Pricing Reflecting Its Mixed Multi Year Share Performance? [Yahoo! Finance]
Low
Report
Is TG Therapeutics (TGTX) Pricing Reflecting Its Mixed Multi Year Share Performance? [Yahoo! Finance]
3/9
07:58 am
tgtx
Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis [Yahoo! Finance]
Low
Report
Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis [Yahoo! Finance]
3/9
07:30 am
tgtx
Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis
Low
Report
Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis
3/9
03:34 am
tgtx
Azer Cel Milestone Broadens TG Therapeutics Autoimmune Pipeline And Valuation Story [Yahoo! Finance]
Low
Report
Azer Cel Milestone Broadens TG Therapeutics Autoimmune Pipeline And Valuation Story [Yahoo! Finance]
3/8
04:33 pm
tgtx
How Investors Are Reacting To TG Therapeutics (TGTX) Adding Azer-cel Milestone to Its MS Portfolio [Yahoo! Finance]
Low
Report
How Investors Are Reacting To TG Therapeutics (TGTX) Adding Azer-cel Milestone to Its MS Portfolio [Yahoo! Finance]
3/8
01:33 pm
tgtx
Assessing TG Therapeutics (TGTX) Valuation After BRIUMVI-Led Earnings And Autoimmune Pipeline Updates [Yahoo! Finance]
Low
Report
Assessing TG Therapeutics (TGTX) Valuation After BRIUMVI-Led Earnings And Autoimmune Pipeline Updates [Yahoo! Finance]
3/8
06:33 am
tgtx
Bank of America Securities Bearish on TG Therapeutics (TGTX) Post Earnings [Yahoo! Finance]
Low
Report
Bank of America Securities Bearish on TG Therapeutics (TGTX) Post Earnings [Yahoo! Finance]
3/6
07:30 am
tgtx
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
Low
Report
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
3/1
04:40 am
tgtx
TG Therapeutics (TGTX) Reports Financial Results for Q4 and Full Year 2025 [Yahoo! Finance]
Low
Report
TG Therapeutics (TGTX) Reports Financial Results for Q4 and Full Year 2025 [Yahoo! Finance]
2/28
07:02 pm
tgtx
TG Therapeutics Five Year BRIUMVI Data And What It Means For Valuation [Yahoo! Finance]
Low
Report
TG Therapeutics Five Year BRIUMVI Data And What It Means For Valuation [Yahoo! Finance]
2/27
09:16 am
tgtx
TG Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
TG Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
2/26
05:37 pm
tgtx
TG Therapeutics Inc (TGTX) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]
Low
Report
TG Therapeutics Inc (TGTX) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]
2/26
02:17 pm
tgtx
TG Therapeutics (TGTX) Q4 2025 Earnings Transcript [Yahoo! Finance]
Low
Report
TG Therapeutics (TGTX) Q4 2025 Earnings Transcript [Yahoo! Finance]
2/26
12:37 pm
tgtx
TG Therapeutics outlines $825M–$850M BRIUMVI 2026 guidance while accelerating subcutaneous program [Seeking Alpha]
Neutral
Report
TG Therapeutics outlines $825M–$850M BRIUMVI 2026 guidance while accelerating subcutaneous program [Seeking Alpha]
2/26
07:32 am
tgtx
TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance [Yahoo! Finance]
High
Report
TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance [Yahoo! Finance]
2/26
07:00 am
tgtx
TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance
Medium
Report
TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance
2/23
08:03 am
tgtx
TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update [Yahoo! Finance]
Medium
Report
TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update [Yahoo! Finance]
2/23
07:30 am
tgtx
TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update
Medium
Report
TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update
2/17
07:30 am
tgtx
Long Term Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI in Relapsing Multiple Sclerosis
Low
Report
Long Term Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI in Relapsing Multiple Sclerosis
2/14
01:32 am
tgtx
TG Therapeutics (NASDAQ:TGTX) was downgraded by analysts at
Wall Street
Low
Report
TG Therapeutics (NASDAQ:TGTX) was downgraded by analysts at
Wall Street
2/8
04:17 pm
tgtx
TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis
Medium
Report
TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis
2/7
03:48 am
tgtx
TG Therapeutics (TGTX) Sees Price Target Drop from JPMorgan [Yahoo! Finance]
Medium
Report
TG Therapeutics (TGTX) Sees Price Target Drop from JPMorgan [Yahoo! Finance]
2/6
07:30 am
tgtx
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
Low
Report
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum